Summary: A new preclinical study provides the first proof-of-concept that an mRNA vaccine can target neuroblastoma, the most lethal childhood cancer. The research addresses a cancer responsible for roughly 15% of pediatric cancer deaths and for which many high-risk patients—about 80%—do not respond to existing therapies.
Using an advanced delivery system, researchers developed self-assembling peptide nanoparticles that deliver mRNA directly to immune cells and tumor sites. The vaccine educates the immune system to recognize Glypican 2 (GPC2), a protein frequently and abundantly displayed on neuroblastoma cells. In animal models, this targeted immunotherapy reduced tumor volume by about 70% and delayed the onset of aggressive tumor growth by 10–11 days, demonstrating substantial therapeutic potential.
Key Facts
- 70% Tumor Reduction: In preclinical testing, the mRNA vaccine reduced neuroblastoma tumor volume by approximately 70% compared with unvaccinated controls.
- Slowed Progression: Vaccinated animals showed a 10–11 day delay in tumor development in an aggressive neuroblastoma model.
- Target: Glypican 2 (GPC2): The vaccine directs immune responses against GPC2, a cell-surface protein overexpressed in neuroblastoma and present in several other cancer types.
- Modular Design: The delivery system is modular, allowing components to be exchanged to match a patient’s tumor profile and enabling rapid adaptation to different targets.
- Clinical Need: Neuroblastoma remains a major cause of childhood cancer mortality, with a high proportion of high-risk cases resistant to standard treatment.
Source: RCSI
A new study from RCSI University of Medicine and Health Sciences presents a novel strategy for anticancer vaccine development. The work reports the first preclinical evidence that an mRNA vaccine can effectively target neuroblastoma, offering a potential new approach for this challenging disease.
The research team, led by Dr. Olga Piskareva, Senior Lecturer in the RCSI Department of Anatomy and Regenerative Medicine, evaluated an mRNA vaccine formulated with peptide-based carriers to test its activity against neuroblastoma tumors in mice.
The vaccine prompts the immune system to recognize and attack neuroblastoma cells, producing a strong antigen-specific response. In the study’s murine model, immunized animals experienced a pronounced decrease in tumor volume and a delay in tumor onset, signaling meaningful anti-tumor activity.
Despite therapeutic advances, neuroblastoma remains a leading cause of childhood cancer deaths, accounting for about 15% of fatalities. In Ireland, five to ten new cases are diagnosed annually. Many high-risk patients do not respond to current treatments, which highlights the need for new therapeutic strategies.
Dr. Piskareva described the mRNA approach as modular: “The mRNA vaccine technology is like LEGO bricks. By combining different components, we can tailor the vaccine precisely to the needs of individual patients. This pilot study demonstrates promising potential for anticancer vaccines against neuroblastoma and marks an important early milestone in mRNA vaccine development for this disease.”
The vaccine uses tiny self-assembling peptide nanoparticles—designed to deliver mRNA encoding GPC2—to activate immune cells against this tumor-associated antigen. Because GPC2 is also expressed in various other cancers, the platform could be repurposed to target a broader range of tumors, making it a versatile tool for future cancer immunotherapies.
Recurrent neuroblastoma is notably difficult to treat because tumors often become resistant to standard therapies after relapse. Approaches that stimulate the immune system with a distinct mechanism of action, such as the mRNA vaccine described here, provide an alternative strategy that could improve outcomes for patients with hard-to-treat disease.
Funding: The research was conducted in collaboration with the School of Pharmacy at Queen’s University Belfast and supported by the Irish Research Council (IRC), the Higher Education Authority (HEA), the Health Research Board (HRB), and the Conor Foley Neuroblastoma Cancer Research Foundation.
Key Questions Answered:
A: The vaccine packages mRNA inside self-assembling peptide nanoparticles that deliver genetic instructions to immune cells. Those instructions encode GPC2, prompting the body to produce proteins that prime T cells and other immune effectors to recognize and kill cells displaying GPC2, which are characteristic of neuroblastoma. This targeted immune activation helps clear tumor cells while sparing most normal tissue.
A: Neuroblastoma can be extremely aggressive and adaptable. High-risk cases frequently do not respond to standard therapies, and relapsed tumors often acquire resistance to conventional drugs. These clinical challenges make novel approaches—especially those using the immune system—to be of great importance.
A: The analogy highlights the platform’s modularity. The vaccine’s delivery vehicle and the encoded antigens can be interchanged, allowing scientists to rapidly redesign or personalize vaccines to target different tumor antigens or adapt to changes in a tumor’s biology.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The original journal paper was reviewed in full.
- Additional explanatory context was added by staff for clarity.
About this genetics and brain cancer research news
Author: Laura Anderson
Source: RCSI
Contact: Laura Anderson – RCSI
Image: Image credited to Neuroscience News
Original Research: Open access. “mRNA vaccination using peptide nanoparticles triggers a strong immune response against endogenous GPC2 in a murine neuroblastoma model” by Ellen King, Chayanika Saha, Rabia Saleem, Binyumeng Jiang, Eve O’Donoghue, Federica Cottone, Helen O. McCarthy, Olga Piskareva. Molecular Therapy Oncology. DOI: 10.1016/j.omton.2026.201244
Abstract
mRNA vaccination using peptide nanoparticles triggers a strong immune response against endogenous GPC2 in a murine neuroblastoma model
Neuroblastoma is an aggressive pediatric solid tumor that arises during embryonic development and accounts for roughly 15% of cancer-related deaths in children. Until now, there has been no published experimental or clinical data demonstrating the effectiveness of an mRNA vaccine for neuroblastoma.
This study introduces a first-in-class mRNA vaccine for neuroblastoma. The team used the self-assembling peptide RALA to deliver mRNA encoding mouse GPC2 (mGPC2). The work includes detailed in vitro characterization of nanoparticle formulations, cellular uptake assays, and functional tests. Vaccinated mice developed a strong antigen-specific cellular immune response, with increased IFN-γ and IL-2 production by splenocytes and elevated TNF-α expression in both CD4+ and CD8+ T cells.
In a subcutaneous murine model of MYCN-amplified neuroblastoma, immunization delayed tumor development by 10–11 days and reduced tumor volume by about 70% compared with unvaccinated controls. These results support the therapeutic promise of the RALA/mGPC2 vaccine for neuroblastoma.
Because GPC2 is also upregulated in several adult and pediatric cancers, this vaccine platform could be adapted to target other tumor types, offering broader potential for cancer immunotherapy development.